Overview
Background
Peter Csurhes is an immunologist with a strong research track record in multiple sclerosis (MS) research within UQ that has spanned 30 years.
Together with Emeritus Professor Michael Pender, Peter’s work in a number of preclinical research studies into the role that immunity to Epstein-Barr virus (EBV) plays in MS disease pathogenesis has translated to clinical trials testing of potentially ground-breaking new T cell immunotherapeutic treatments for progressive MS. Collaborative links between QIMR Berghofer, Royal Brisbane and Women’s Hospital and commercial partners have been established and clinical trials are ongoing.
After the retirement of Professor Pender, Peter has taken on a chief investigator role, and in 2023 gained successful NHMRC MRFF funding to continue research into the biology of the Epstein-Barr virus and the role it plays in the multiple sclerosis disease process.
Peter has also been involved in studying the role of reactivity to autoantigens in MS and in diseases of the peripheral nervous system including Guillain-Barre syndrome and CIDP.
For several years he worked on the immunology of potential malaria vaccine candidates and also worked part-time for 18 months on research into EBV-related cancers within the QIMR-Berghofer Medical Research Institute.
Availability
- Mr Peter Csurhes is:
- Not available for supervision
Fields of research
Qualifications
- Bachelor (Honours) of Science (Advanced), The University of Queensland
Works
Search Professor Peter Csurhes’s works on UQ eSpace
2021
Journal Article
Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy
Ioannides, Zara A., Csurhes, Peter A., Douglas, Nanette L., Mackenroth, Gem, Swayne, Andrew, Thompson, Kate M., Hopkins, Tracey J., Green, Kerryn A., Blum, Stefan, Hooper, Kaye D., Wyssusek, Kerstin H., Coulthard, Alan and Pender, Michael P. (2021). Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy. Frontiers in Neurology, 12 652811, 652811. doi: 10.3389/fneur.2021.652811
2021
Journal Article
Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis
Ioannides, Zara A., Csurhes, Peter A., Swayne, Andrew, Foubert, Philippe, Aftab, Blake T. and Pender, Michael P. (2021). Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis. Multiple Sclerosis Journal Experimental, Translational and Clinical, 7 (2), 1-12. doi: 10.1177/20552173211019772
2020
Journal Article
Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis
Pender, Michael P., Csurhes, Peter A., Smith, Corey, Douglas, Nanette L., Neller, Michelle A., Matthews, Katherine K., Beagley, Leone, Rehan, Sweera, Crooks, Pauline, Hopkins, Tracey J., Blum, Stefan, Green, Kerryn A., Ioannides, Zara A., Swayne, Andrew, Aftab, Blake T., Hooper, Kaye D., Burrows, Scott R., Thompson, Kate M., Coulthard, Alan and Khanna, Rajiv (2020). Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI insight, 5 (20) e144624. doi: 10.1172/jci.insight.144624
2018
Journal Article
Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
Pender, Michael P., Csurhes, Peter A., Smith, Corey, Douglas, Nanette L., Neller, Michelle A., Matthews, Katherine K., Beagley, Leone, Rehan, Sweera, Crooks, Pauline, Hopkins, Tracey J., Blum, Stefan, Green, Kerryn A., Ioannides, Zara A., Swayne, Andrew, Aftab, Blake T., Hooper, Kaye D., Burrows, Scott R., Thompson, Kate M., Coulthard, Alan and Khanna, Rajiv (2018). Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis. JCI Insight, 3 (22) e124714. doi: 10.1172/jci.insight.124714
2017
Journal Article
Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis
Pender, Michael P., Csurhes, Peter A., Burrows, Jacqueline M. and Burrows, Scott R. (2017). Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clinical and Translational Immunology, 6 (1) e126, 1-17. doi: 10.1038/cti.2016.87
2017
Conference Publication
Safety and clinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T-cell therapy in patients with progressive multiple sclerosis
Pender, M. P., Csurhes, P. A., Smith, C., Douglas, N. L., Neller, M. A., Beagley, L., Rehan, S., Hopkins, T. J., Thompson, K. M., Blum, S., Green, K. A., Ioannides, Z. A., Coulthard, A., Hooper, K. D., Burrows, S. R. and Khanna, R. (2017). Safety and clinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T-cell therapy in patients with progressive multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications.
2017
Conference Publication
Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein-Barr virus-specific T cell therapy: interim results of a phase I trial
Pender, Michael, Csurhes, Peter, Smith, Corey, Douglas, Nanette, Neller, Michelle, Beagley, Leone, Rehan, Sweera, Hopkins, Tracey, Thompson, Kate, Blum, Stefan, Green, Kerryn, Ioannides, Zara, Coulthard, Alan, Hooper, Kaye, Burrows, Scott and Khanna, Rajiv (2017). Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein-Barr virus-specific T cell therapy: interim results of a phase I trial. 69th Annual Meeting of the American Academy of Neurology (AAN), Boston, Massachusetts, 22-28 April 2017. Philadelphia, PA, United States: Lippincott Williams & Wilkins.
2015
Journal Article
Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: effect on outcome
Chan, Adeline, Yan, Jun, Csurhes, Peter, Greer, Judith and McCombe, Pamela (2015). Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: effect on outcome. Journal of Neuroimmunology, 286, 42-47. doi: 10.1016/j.jneuroim.2015.06.013
2015
Journal Article
The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in
Blum, Stefan, Csurhes, Peter and McCombe, Pamela (2015). The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in. Journal of Neuroimmunology, 285, 53-56. doi: 10.1016/j.jneuroim.2015.05.017
2015
Conference Publication
Impaired T cell control of Epstein-Barr virus infection in multiple sclerosis
Pender, Michael, Csurhes, Peter and Burrows, Scott (2015). Impaired T cell control of Epstein-Barr virus infection in multiple sclerosis. MS Research Australia Progress in MS Research Conference, Melbourne, Australia, Oct 29-30, 2015. London, EC1Y 1SP United Kingdom: SAGE PUBLICATIONS LTD. doi: 10.1177/1352458515616527
2014
Journal Article
Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis
Pender, Michael P., Csurhes, Peter A., Smith, Corey, Beagley, Leone, Hooper, Kaye D., Raj, Meenakshi, Coulthard, Alan, Burrows, Scott R. and Khanna, Rajiv (2014). Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Multiple Sclerosis Journal, 20 (11), 1541-1544. doi: 10.1177/1352458514521888
2014
Journal Article
Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barré Syndrome
Blum, Stefan, Csurhes, Peter, Reddel, Stephen, Spies, Judy and McCombe, Pamela (2014). Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barré Syndrome. Journal of Neuroimmunology, 267 (1-2), 92-96. doi: 10.1016/j.jneuroim.2013.12.007
2014
Journal Article
Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis
Pender, Michael P., Csurhes, Peter A., Pfluger, Casey M. M. and Burrows, Scott R. (2014). Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis. Multiple Sclerosis Journal, 20 (14), 1825-1832. doi: 10.1177/1352458514536252
2014
Conference Publication
Killer immunoglobulin-like receptors and their HLA ligands in Guillain-Barré syndrome
Blum, Stefan, Csurhes, Peter, Reddel, Stephen, Spies, Judy and McCombe, Pamela (2014). Killer immunoglobulin-like receptors and their HLA ligands in Guillain-Barré syndrome. ANZAN Annual Scientific Meeting 2014, Adelaide, South Australia, Australia, May 2014. Elsevier. doi: 10.1016/j.jocn.2014.06.032
2013
Conference Publication
Treatment of secondary progressive multiple sclerosis by boosting CD8 T cell immunity to Epstein-Barr virus using a novel adoptive immunotherapy
Pender, M. P., Csurhes, P. A., Smith, C., Beagley, L., Hooper, K. D., Raj, M., Coulthard, A., Burrows, S. R. and Khanna, R. (2013). Treatment of secondary progressive multiple sclerosis by boosting CD8 T cell immunity to Epstein-Barr virus using a novel adoptive immunotherapy. 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen Denmark, 2 - 5 October 2013. London, United Kingdom: Sage Publications Ltd.. doi: 10.1177/1352458513502429
2012
Journal Article
CD8(+) T cells far predominate over CD4(+) T cells in healthy immune response to Epstein-Barr virus infected lymphoblastoid cell lines
Pender, Michael P., Csurhes, Peter A., Pfluger, Casey M. M. and Burrows, Scott R. (2012). CD8(+) T cells far predominate over CD4(+) T cells in healthy immune response to Epstein-Barr virus infected lymphoblastoid cell lines. Blood, 120 (25), 5085-5087. doi: 10.1182/blood-2012-06-437285
2012
Journal Article
CD8 T cell deficiency impairs control of Epstein–Barr virus and worsens with age in multiple sclerosis
Pender, Michael P., Csurhes, Peter A., Pfluger, Casey M.M. and Burrows, Scott R. (2012). CD8 T cell deficiency impairs control of Epstein–Barr virus and worsens with age in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 83 (3), 353-354. doi: 10.1136/jnnp-2011-300213
2012
Journal Article
Interleukin-6 Gene Promoter-572 C Allele may play a role in rate of disease progression in Multiple Sclerosis
Yan, Jun, Liu, Jia, Lin, Clement Yihao, Australia and New Zealand Multiple Sclerorsis Genetics Consortium, Csurhes, Peter A., Pender, Michael P., McCombe, Pamela A. and Greer, Judith M. (2012). Interleukin-6 Gene Promoter-572 C Allele may play a role in rate of disease progression in Multiple Sclerosis. International Journal of Molecular Sciences, 13 (10), 13667-13679. doi: 10.3390/ijms131013667
2011
Conference Publication
CD8+T cell deficiency impairs control of Epstein-Barr virus and worsens with age in multiple sclerosis
Pender, M. P., Csurhes, P. A., Pfluger, C. M. M. and Burrows, S. R. (2011). CD8+T cell deficiency impairs control of Epstein-Barr virus and worsens with age in multiple sclerosis. LONDON: SAGE PUBLICATIONS LTD.
2011
Journal Article
Decreased CD8(+) T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes
Pender, Michael P., Csurhes, Peter A ., Pfluger, Casey M. M. and Burrows, Scott R. (2011). Decreased CD8(+) T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes. BMC Neurology, 11 (1) 95, 95-1-95-6. doi: 10.1186/1471-2377-11-95
Funding
Current funding
Media
Enquiries
For media enquiries about Mr Peter Csurhes's areas of expertise, story ideas and help finding experts, contact our Media team: